ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2013

General Practice

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,727Medicare Part D Prescriptions Filled, Including Refills

Rank: 1 out of 15

$613K Total Retail Price of All Prescriptions

Rank: 1 out of 15

528 Patients Receiving at Least One Drug in Part D
73% Patients 65 Years and Older
39% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg 81928cdb0ebe162ff75cf405bfacadd396bf3ec84bc467b6f3e612dd63daa776 Average for
this specialty
in Nevada
Lower avg 72b1978e1dcc0b845f89d17d692cfff7aeaf8d8bce70310d8bfc535db2daf62a

Schedule Two
Controlled Substances

7% of this provider’s 528 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

24% of this provider’s 528 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Brand Name Drugs

16% of this provider’s prescriptions were for brand-name drugs, compared to an average of 18%.

Prescription Price

$63 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

18 is the average number of prescriptions (including refills) per patient, compared to an average of 13.


This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

B

A benzodiazepine, or tranquilizer. More » The American Geriatrics Society says these drugs increase the risk of cognitive impairment, delirium, falls and fractures in older adults.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled with Refills Prescriptions
to 65+
Patients Recieving this Drug Category For this Prescriber For All Prescribers in
This Specialty in Nevada
LISINOPRIL 562 415 167 1 1
HYDROCODONE-ACETAMINOPHEN 532 361 110 S3 2 2
AMLODIPINE BESYLATE 450 357 134 3 3
SIMVASTATIN 419 332 131 4 5
METFORMIN HCL 376 292 106 5 6
ATORVASTATIN CALCIUM 361 290 116 6 10
OMEPRAZOLE 298 213 101 7 7
LEVOTHYROXINE SODIUM 244 188 69 8 3
METOPROLOL TARTRATE 188 170 57 9 8
HYDROCHLOROTHIAZIDE 161 116 46 10 10
CLOPIDOGREL 149 126 50 11 25
FUROSEMIDE 144 116 64 12 9
LOSARTAN POTASSIUM 138 101 44 13 16
ATENOLOL 134 113 35 14 12
GLIPIZIDE 123 91 40 15 15
GABAPENTIN 122 83 50 16 14
TRAMADOL HCL 115 90 53 17 33
LISINOPRIL-HYDROCHLOROTHIAZIDE 109 104* 34 18 21
GLIPIZIDE ER 103 82 30 19 50
METOPROLOL SUCCINATE 100 86 30 20 26
LOVASTATIN 100 95* 31 20 13
MELOXICAM 99 78 40 22 34
RANITIDINE HCL 98 69 38 23 28
AZITHROMYCIN 98 75 84 23 19
BD ULTRA-FINE PEN NEEDLE 94 63 30 25 52
CARVEDILOL 94 66 37 25 22
POTASSIUM CHLORIDE 92 77 42 27 29
HYDRALAZINE HCL 83 57 27 28 54
PRAVASTATIN SODIUM 81 76* 25 29 18
LOSARTAN-HYDROCHLOROTHIAZIDE 80 75* 26 30 42
WARFARIN SODIUM 79 59 22 31 27
CLONIDINE HCL 78 48 25 32 30
LANTUS SOLOSTAR 75 51 27 33 55
ALENDRONATE SODIUM 75 70* 27 33 20
MORPHINE SULFATE ER 73 <11 <11 S2 35 56
NAPROXEN 71 54 34 36 58
VENTOLIN HFA 71 49 41 36 58
OXYCODONE HCL-ACETAMINOPHEN 69 <11 <11 S2 38 60
JANUVIA 63 47 22 39 66
SPIRIVA 61 50 21 40 37
TRIAMTERENE-HCTZ 60 45 17 41 67
OXYCODONE-ACETAMINOPHEN 60 55* 16 S2 41 67
VALSARTAN-HYDROCHLOROTHIAZIDE 60 55* 14 41 67
AMLODIPINE BESYLATE-BENAZEPRIL 57 41 15 44 71
PANTOPRAZOLE SODIUM 56 35 19 45 73
KLOR-CON 10 53 48* 19 46 80
PROAIR HFA 51 29 23 47 45
SERTRALINE HCL 50 45* 15 48 35
About This Data

Prescribing data from Medicare’s prescription drug benefit, known as Part D, was compiled and released by the Centers for Medicare and Medicaid Services, the federal agency that oversees the program. ProPublica combined that data with additional information released by CMS. The data for 2013 includes nearly 1.4 billion prescriptions written by 1.3 million doctors, nurses and other providers. This database lists about 410,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths of these prescriptions went to patients 65 and older; the rest were for disabled patients Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to checkup@propublica.org and we will update your information. If you have other questions about this data, send a note to checkup@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.